Superworth

Inhibrx Biosciences price to book ratio INBX

Market value divided by the book value of the company's net assets, since 2024.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
161×
Apr 2026
Peer median
5.4×

Inhibrx Biosciences' price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Apr 2026, at 161×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far161×27.1×161×
202531.7×1.0×35.3×
20241.2×0.8×1.3×

Against its peers

Companies in Biotechnology nearest Inhibrx Biosciences' size, closest first, today.

CompanyPrice to book ratio
INBXInhibrx Biosciencesn/m
MGTXMeiraGTx4.1×
VCELVericel5.9×
ADMAAdma Biologics5.9×
PLXProtalix BioTherapeutics2.9×
KRYSKrystal Biotech6.8×
RGENRepligen4.7×
TECHBIO-TECHNE5.4×
Peer median5.4×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Inhibrx Biosciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.